Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Envisia Therapeutics To Present At American Glaucoma Society 2017 Annual Meeting | ||
By: PR Newswire Association LLC. - 02 Mar 2017 | Back to overview list |
|
RESEARCH TRIANGLE PARK, N.C., March 2, 2017 /PRNewswire/ -- Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today announced that it will present a podium presentation and two posters at the American Glaucoma Society (AGS) Annual Meeting being held March 2-6, 2017 in San Diego, CA. "We are honored to have the opportunity to present a comprehensive data set from our ENV515 glaucoma program and look forward to engaging in scientific exchange among our peers at the AGS Annual Meeting," said Benjamin Yerxa, PhD, President of Envisia Therapeutics. "The data that will be presented highlight the potential of our investigational ENV515 travoprost extended-release product to become a once-a-year therapy for intraocular pressure (IOP) control in glaucoma patients." All Envisia presentations will take place on Friday, March 3; details are as follows: Oral presentation PA09: Interim Analysis of Low Dose ENV515 Travoprost XR with 9 Month Duration and IOP-Lowering Effects of Pre-Study PGAs and In-Study Timolol Ballroom, Hotel Del Coronado, Coronado, California, 8:41 AM Poster Presentation PO097: Design and Development of ENV515 Intraocular Applicator Including Custom Needle for Intracameral Injections of ENV515 Travoprost Extended Release (XR) Therapy for Glaucoma Poster Presentation PO090: Changing the Paradigm of PGA Dosing in Glaucoma with Extended Release Formulations: Continuous PGA Release Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 9 Months without Any Attenuation in IOP-lowering Effect ABOUT ENVISIA THERAPEUTICS™ Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.
SOURCE Envisia Therapeutics |
||
|
||
Copyright 2017 PR Newswire Association LLC. | Back to overview list |